Details of the Drug Combination

General Information of Drug Combination (ID: DCIEKTI)

Drug Combination Name
METHYLENEDIOXYMETHAMPHETAMINE METHYLENEDIOXYMETHAMPHETAMINE
Indication
Disease Entry Status REF
Schizophrenia Phase 1 [1]
Component Drugs METHYLENEDIOXYMETHAMPHETAMINE   DMYVU47 METHYLENEDIOXYMETHAMPHETAMINE   DMYVU47
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of METHYLENEDIOXYMETHAMPHETAMINE
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
METHYLENEDIOXYMETHAMPHETAMINE Interacts with 7 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [3]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [3]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [3]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [3]
Synaptic vesicle amine transporter (SLC18A2) TTNZRI3 VMAT2_HUMAN Antagonist [3]
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [3]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTT(s)
METHYLENEDIOXYMETHAMPHETAMINE Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [4]
Catechol O-methyltransferase (COMT) DEV3T4A COMT_HUMAN Metabolism [4]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Metabolism [5]
------------------------------------------------------------------------------------
METHYLENEDIOXYMETHAMPHETAMINE Interacts with 22 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Activity [6]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [6]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Decreases Activity [7]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [8]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Activity [9]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [8]
Lysosome-associated membrane glycoprotein 2 (LAMP2) OTLUGEJC LAMP2_HUMAN Increases Expression [10]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Activity [11]
Sodium-dependent noradrenaline transporter (SLC6A2) OTMHQJMP SC6A2_HUMAN Decreases Activity [12]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Decreases Activity [12]
Neuronal acetylcholine receptor subunit alpha-7 (CHRNA7) OTBUSUTE ACHA7_HUMAN Increases Activity [13]
Monocarboxylate transporter 1 (SLC16A1) OTW1UTZ7 MOT1_HUMAN Increases Expression [14]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Expression [8]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [8]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [8]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [10]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [8]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [8]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [8]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Affects Response To Substance [15]
Oxytocin receptor (OXTR) OT7WFW4U OXYR_HUMAN Affects Response To Substance [16]
Arylamine N-acetyltransferase 2 (NAT2) OTBPDQOY ARY2_HUMAN Increases Acetylation [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DOT(s)
Indication(s) of METHYLENEDIOXYMETHAMPHETAMINE
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
METHYLENEDIOXYMETHAMPHETAMINE Interacts with 7 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [3]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [3]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [3]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [3]
Synaptic vesicle amine transporter (SLC18A2) TTNZRI3 VMAT2_HUMAN Antagonist [3]
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [3]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTT(s)
METHYLENEDIOXYMETHAMPHETAMINE Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [4]
Catechol O-methyltransferase (COMT) DEV3T4A COMT_HUMAN Metabolism [4]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Metabolism [5]
------------------------------------------------------------------------------------
METHYLENEDIOXYMETHAMPHETAMINE Interacts with 22 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Activity [6]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [6]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Decreases Activity [7]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [8]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Activity [9]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [8]
Lysosome-associated membrane glycoprotein 2 (LAMP2) OTLUGEJC LAMP2_HUMAN Increases Expression [10]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Activity [11]
Sodium-dependent noradrenaline transporter (SLC6A2) OTMHQJMP SC6A2_HUMAN Decreases Activity [12]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Decreases Activity [12]
Neuronal acetylcholine receptor subunit alpha-7 (CHRNA7) OTBUSUTE ACHA7_HUMAN Increases Activity [13]
Monocarboxylate transporter 1 (SLC16A1) OTW1UTZ7 MOT1_HUMAN Increases Expression [14]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Expression [8]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [8]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [8]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [10]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [8]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [8]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [8]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Affects Response To Substance [15]
Oxytocin receptor (OXTR) OT7WFW4U OXYR_HUMAN Affects Response To Substance [16]
Arylamine N-acetyltransferase 2 (NAT2) OTBPDQOY ARY2_HUMAN Increases Acetylation [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DOT(s)

References

1 ClinicalTrials.gov (NCT05770375) Tolerability of MDMA in Schizophrenia
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4574).
3 The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
4 Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr;26(2):137-44.
5 The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
6 An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine. Toxicol In Vitro. 2014 Mar;28(2):231-9.
7 Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicol Lett. 2016 Jan 22;243:48-55.
8 An insight into the hepatocellular death induced by amphetamines, individually and in combination: the involvement of necrosis and apoptosis. Arch Toxicol. 2013 Dec;87(12):2165-85. doi: 10.1007/s00204-013-1082-9. Epub 2013 Jul 3.
9 P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. Addict Biol. 2003 Dec;8(4):413-8. doi: 10.1080/13556210310001646475.
10 Lysosomal Dysfunction and Autophagy Blockade Contribute to MDMA-Induced Neurotoxicity in SH-SY5Y Neuroblastoma Cells. Chem Res Toxicol. 2020 Apr 20;33(4):903-914. doi: 10.1021/acs.chemrestox.9b00437. Epub 2020 Mar 27.
11 Amphetamines induce tissue factor and impair tissue factor pathway inhibitor: role of dopamine receptor type 4. Eur Heart J. 2010 Jul;31(14):1780-91. doi: 10.1093/eurheartj/ehp598. Epub 2010 Jan 29.
12 Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100. doi: 10.1016/j.neuro.2019.02.011. Epub 2019 Feb 15.
13 The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. Toxicol Appl Pharmacol. 2010 May 1;244(3):344-53. doi: 10.1016/j.taap.2010.01.014. Epub 2010 Feb 2.
14 Modulation of butyrate transport in Caco-2 cells. Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):325-36. doi: 10.1007/s00210-008-0372-x. Epub 2008 Nov 21.
15 Involvement of free radicals in MDMA-induced neurotoxicity in mice. Ann Med Interne (Paris). 2001 Apr;152 Suppl 3:IS57-9.
16 Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. PLoS One. 2018 Jun 18;13(6):e0199384. doi: 10.1371/journal.pone.0199384. eCollection 2018.
17 N-acetyltransferase 2 genetic polymorphism modifies genotoxic and oxidative damage from new psychoactive substances. Arch Toxicol. 2023 Jan;97(1):189-199. doi: 10.1007/s00204-022-03383-2. Epub 2022 Sep 23.